140 related articles for article (PubMed ID: 27777442)
1. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease.
Asano T; Matsuoka KI; Iyama S; Ohashi K; Inamoto Y; Ohwada C; Murata M; Satake A; Yoshida C; Nakase K; Mori Y; Tanimoto M
Acta Med Okayama; 2016 Oct; 70(5):429-433. PubMed ID: 27777442
[TBL] [Abstract][Full Text] [Related]
2. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
3. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
[TBL] [Abstract][Full Text] [Related]
9. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
[TBL] [Abstract][Full Text] [Related]
10. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
11. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
12. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
[TBL] [Abstract][Full Text] [Related]
13. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Qian L; Liu M; Shen J; Cen J; Zhao D
Front Immunol; 2020; 11():598359. PubMed ID: 33324415
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Koshy AG; Kim HT; Liegel J; Arnason J; Ho VT; Antin JH; Joyce R; Cutler C; Gooptu M; Nikiforow S; Logan EK; Elavalakanar P; Narcis M; Stroopinsky D; Avigan ZM; Boussi L; Stephenson S; El Banna H; Bindal P; Cheloni G; Avigan DE; Soiffer RJ; Rosenblatt J
Blood; 2023 Jun; 141(24):2932-2943. PubMed ID: 36862975
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.
Kim N; Jeon YW; Nam YS; Lim JY; Im KI; Lee ES; Cho SG
Cytokine; 2016 Feb; 78():22-6. PubMed ID: 26624506
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
18. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Ussowicz M; Musiał J; Mielcarek M; Tomaszewska A; Nasiłowska-Adamska B; Kałwak K; Gorczyńska E; Mariańska B; Chybicka A
Transplant Proc; 2013 Nov; 45(9):3375-80. PubMed ID: 24182819
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
